INCRETIN-BASED CARDIOVASCULAR PROTECTION BEYOND DIABETES: EVIDENCE, MECHANISMS, AND THERAPEUTIC FRONTIERS FROM GLP-1 RECEPTOR AGONISTS TO MULTI-AGONIST THERAPY